Clinical Trials Logo

Filter by:
NCT ID: NCT04398134 Terminated - Chronic Hepatitis B Clinical Trials

A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection

Start date: August 28, 2020
Phase: Phase 2
Study type: Interventional

This Phase 2a study will assess the safety, antiviral activity, and pharmacokinetics (PK) of ABI-H2158 administered once daily for up to 72 weeks in combination with entecavir (ETV) in participants with chronic hepatitis B virus (HBV) infection.

NCT ID: NCT04397692 Terminated - COVID-19 Clinical Trials

Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)

Start date: June 13, 2020
Phase: N/A
Study type: Interventional

The purpose of this open label, randomized, study is to obtain information on the safety and efficacy of 80 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by SARS-CoV-2.

NCT ID: NCT04397510 Terminated - Covid-19 Clinical Trials

Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury

Start date: June 1, 2020
Phase: Phase 4
Study type: Interventional

Randomized, placebo controlled study to determine if nebulized heparin may reduce the severity of lung injury caused by the novel coronavirus, also known as COVID-19

NCT ID: NCT04397029 Terminated - Breast Cancer Clinical Trials

Assessing the Sensitivity of "SureTouchâ„¢" in Women Undergoing Diagnostic and Screening Mammography

Start date: January 4, 2019
Phase: N/A
Study type: Interventional

Prospective, case-control study being conducted to determine the sensitivity of the SureTouch device in detecting known masses at a pre-determined level of specificity.

NCT ID: NCT04396847 Terminated - Clinical trials for Alcohol Use Disorder

Laboratory Screening of Lorcaserin for Alcohol Use Disorder

Start date: October 25, 2019
Phase: Phase 2
Study type: Interventional

Heavy-drinking smokers, including those with alcohol use disorder (AUD), are at increased risk for numerous negative health outcomes relative to those who use alcohol or cigarettes only. Although heavy-drinking smokers are recognized as an important subgroup for clinical and public health interventions, there are presently no approved medications for the joint indication of alcohol reduction and smoking cessation. Based on evidence that the serotonin system plays a role in alcohol and nicotine consumption and relapse, this study aims to examine whether a serotonin medication alters alcohol and nicotine responses in smokers with AUD, informing its potential utility as a candidate therapy for this clinical subgroup.

NCT ID: NCT04396834 Terminated - Smoking Cessation Clinical Trials

Mechanisms of Lorcaserin for Smoking Cessation

Start date: December 4, 2019
Phase: Phase 2
Study type: Interventional

Identifying new medication options is critical for curbing the health burdens of cigarette smoking. Currently approved smoking cessation medications act on nicotinic receptors, and additional work is needed to identify medications with alternate pharmacological targets. Based on evidence that the serotonin system plays a role in nicotine consumption and relapse, this study will examine whether a selective serotonin medication alters smoking-related behaviors and responses to cigarette smoking under controlled conditions, informing its potential utility for smoking cessation.

NCT ID: NCT04396626 Terminated - Breast Cancer Clinical Trials

HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes

Start date: November 18, 2019
Phase:
Study type: Observational

This is a retrospective, observational study that will document the treatment patterns and clinical outcomes of patients diagnosed with HR+/HER2- A/MBC who received CDK4/6i combination therapy with aromatase inhibitors (AI) as the initial endocrine-based therapy in the A/MBC setting.

NCT ID: NCT04396535 Terminated - Clinical trials for Stage IV Lung Cancer AJCC v8

Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

Start date: October 23, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well docetaxel works with or without bintrafusp alfa in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced). Chemotherapy drugs, such as docetaxel, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with bintrafusp alfa, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving docetaxel and bintrafusp alfa in combination may work better in treating non small-cell lung cancer compared to docetaxel alone.

NCT ID: NCT04396340 Terminated - Ovarian Cancer Clinical Trials

First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b

Start date: May 11, 2020
Phase: Phase 1
Study type: Interventional

Phase 1b, a study in high grade serous ovarian cancer and nonsmall cell lung cancer to evaluate the safety and clinical activity of the antibody-drug conjugate (ADC) XMT-1592.

NCT ID: NCT04396106 Terminated - COVID-19 Clinical Trials

Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting

Start date: May 26, 2020
Phase: Phase 2
Study type: Interventional

The objectives of this study are to evaluate the safety, tolerability, antiviral activity and efficacy of AT-527 in adult subjects ≥18 years of age with moderate COVID-19 and risk factors for poor outcomes (such as obesity (BMI>30), hypertension, diabetes or asthma). Eligible subjects will be randomized to blinded AT-527 (nucleotide analog) tablets or matching placebo tablets to be administered orally for 5 days. Part A will evaluate an AT-527 dose of 550 mg BID and Part B will evaluate a second dose of AT-527 (1100 mg BID). Local supportive standard of care (SOC) will be allowed for all subjects. Efficacy, antiviral activity and safety observations will be compared for treatment with active AT-527 tablets vs. placebo tablets.